Last month CML participated in RFMW’s Annual NA and European Sales Conference. This was a great opportunity to spend a lot of time with th...
December 2022: Liam Devlin answers questions from Microwave Product Digest in the 2023 edition of its annual “View from the Top” feature. Topics include the defence market and mmWave deployment. Click here to read the article. Q&A with David Collins, our recent graduate starter Student Circuit...
Conference|ASH Annual Meeting and Exposition Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs. Olverembatinib (HQP...
RFMW’s Annual NA and European Sales Conference 04 October 2019 Last month CML participated in RFMW’s Annual NA and European Sales Conference. This was... Read More Direct Conversion: After nearly 200 years of radio, we’re still finding ways to improve it 23 September 2019 While the ...
Presented at: ASH 63rd Annual Meeting and Exposition; Atlanta, GA; December 11–14, 2021. Abstract 307. 49. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib...